First and only therapy approved by Health Canada for the treatment of pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis

Launch of KORSUVA in Canada is expected in the second quarter of 2023

MONTREAL , Aug. 16, 2022 /CNW/ - Otsuka Canada Pharmaceutical Inc. (OCPI) today announced that Health Canada has approved KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis.1 KORSUVA is a first-in-class kappa opioid receptor (KOR) agonist that targets the body's peripheral nervous system. CKD associated pruritus affects an estimated 16,000 Canadians with end-stage renal disease on hemodialysis.2,3

"Chronic kidney disease is a debilitating and life-threatening disease that is vastly underdiagnosed," said Elizabeth Myles , National Executive Director of The Kidney Foundation of Canada. "It's encouraging that new treatment options are being approved for patients with chronic kidney disease –"

Dr. Claudio Rigatto , nephrologist, commented "CKD-aP is a common but under-recognized and under-treated condition, and one of the top 3 priorities identified by hemodialysis patients for further research and innovation. Therefore, it is really great to see a new treatment approved in Canada with the potential to improve the lives of many patients suffering from CKD-aP, that is supported by robust KALM 1&2 randomized clinical trials to demonstrate difelikefalin's efficacy and safety."

"We are very proud to be bringing this new treatment option to Canadian patients. The availability of a first in class treatment for this condition, is highly anticipated in Canada as it represents an important advancement that will address clinical care gaps" – Michael Laranjo , president and general manager of OCPI.

The approval of KORSUVA is based on pivotal clinical data from two phase-III trials, KALM-14 and KALM-25,6, as well as supportive data from an additional 32 clinical studies. These studies showed that treatment with KORSUVA resulted in clinically meaningful improvements in pruritus severity and in pruritus-related quality of life components and was found to be generally well tolerated in patients with moderate-to-severe CKD-associated pruritus.

In April of 2021, OCPI secured exclusive rights from Vifor Fresenius Medical Care Renal Pharma to promote and distribute KORSUVA in Canada . OCPI expects to launch KORSUVA in Canada in the second quarter of 2023 upon supply availability. KORSUVA, developed by Cara Therapeutics, is also approved in the United States , as well as in the European Union and Great Britain under the brand name Kapruvia®.

OCPI is an innovative, fast-growing health care company that commercializes novel medicines in Canada . OCPI aims to improve the quality of life and health of patients through its commitments to neuroscience, cardio-renal, and nephrology. OCPI was established in 2010, with headquarters in Saint-Laurent , Quebec.

OCPI is part of Otsuka Pharmaceutical Co., Ltd., a global healthcare company with the corporate philosophy: "Otsuka – people   creating   new   products   for better   health   worldwide." Otsuka Pharmaceutical Co., Ltd., researches, develops, manufactures, and markets innovative and original products, with a focus on pharmaceutical products for the treatment of diseases and nutraceutical products for the maintenance of everyday health.

Otsuka Pharmaceutical is a wholly owned subsidiary of Otsuka Holdings Co., Ltd., based in Tokyo, Japan . The Otsuka group of companies employs approximately 47,000 people worldwide and had consolidated sales of approximately USD 13.6 billion in 2021.

All Otsuka stories start by taking the road less travelled. Learn more about Otsuka on our global website at https://www.otsuka.co.jp/en. Learn more about Otsuka in Canada at www.otsukacanada.com.

KORSUVA is a registered trademark of Cara Therapeutics used under license by OCPI.

About Chronic Kidney Disease-associated Pruritus (CKD-aP)

Chronic Kidney Disease-associated Pruritus (CKD-aP) is an intractable systemic itch condition that occurs with high frequency and intensity in patients with chronic kidney disease undergoing dialysis. Pruritus has also been reported in patients with stage III-V CKD who are not on dialysis. Aggregate, longitudinal, multi-country studies estimate the weighted prevalence of CKD-aP to be approximately 40% in patients with end-stage renal disease (ESRD), with approximately 25% of patients reporting severe pruritus. The majority of dialysis patients (approximately 60 to 70%) report pruritus, with 30 to 40% reporting moderate or severe pruritus.3,7,8 Recent data from the ITCH National Registry Study showed that, among those with pruritus, approximately 59% experienced symptoms daily or nearly daily for more than a year. Given its association with CKD/ESRD, most afflicted patients will continue to have symptoms for months or years, with currently employed antipruritic treatments, such as antihistamines and corticosteroids, unable to provide consistent, adequate relief. Moderate-to-severe chronic pruritus has repeatedly been shown to directly decrease quality of life, contribute to symptoms that impair quality of life (such as poor sleep quality), and is associated with depression.9 CKD-aP is also an independent predictor of mortality among hemodialysis patients, mainly related to increased risk of inflammation and infections.

Product Monograph, August 12, 2022,  Korsuva ( difelikefalin) indication:      

Canadian Institute for Health Information. Treatment of End-Stage Organ Failure in Canada, Canadian Organ Replacement Register, 2011 to 2020: End-Stage Kidney Disease and Kidney Transplants — Data Tables. Ottawa, ON: CIHI; 2021

Sukul et al. Self-reported Pruritus and Clinical, Dialysis-Related, and Patient-Reported Outcomes in Hemodialysis Patients. Kidney Med. 2020 Nov 21;3(1):42-53.

Fishbane S, et al. A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus. N Engl J Med 2020;382:222-32

Topf J, et al. Efficacy of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Q1 Q2 Analysis of KALM-1 and KALM-2 Phase 3 Studies. Kidney Med (Article in Press) 2022

Fishbane S, et al. Safety and Tolerability of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Q1 Pooled Analysis From the Phase 3 Clinical Trial Program. Kidney Med (Article in Press) 2022

Ramakrishnan K, et al. Clinical characteristics and outcomes of end-stage renal disease patients with self-reported pruritus symptoms. International Journal of Nephrology and Renovascular Disease. 2014; 7: 1-12.

Pisoni RL, et al. Pruritus in haemodialysis patients: international results from the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant. 2006; 21:3495-3505

Mathur VS, et al. A longitudinal study of Uremic Pruritus in hemodialysis patients. Clin J Am Soc Nephrol. 2010; 5(8):1410-1419.

SOURCE Otsuka Canada Pharmaceutical Inc.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/August2022/16/c0829.html

The FDA is convening an adcomm meeting of its Pulmonary-Allergy Drugs Advisory Committee, slated for October 6, to discuss Veru Inc's (NASDAQ: VERU) request for Emergency Use Authorization of sabizabulin for hospitalized COVID-19 patients at high risk for ARDS. In a public notice, the FDA said that as part of the adcomm, one of the focuses of the experts will include "the treatment effect size in the context of the high placebo mortality rate, the limited size of the safety database, and identif

Regeneron's Eylea eye-disorder drug faces competitive pressure on multiple fronts. New data could cement its dominance.

Nursing homes and debt collectors are billing and suing long-term-care residents’ family members and friends, demanding payments for debts these individuals don’t legally owe, consumer attorneys and federal regulators are claiming. Under federal law, nursing homes participating in Medicare and Medicaid can’t make such provisions a condition of admission or continued stay in the facility.

When planning for the future, health care ranks as one of the highest concerns for both savers and retirees alike. Not only are health care costs rising by more than 5% every year, but rampant inflation and volatile market performances … Continue reading → The post New Bill May Allow Penalty-Free 401(k) Withdrawals for This Retirement Expense appeared first on SmartAsset Blog.

Studies "support aflibercept 8 mg as a potential new standard-of-care," Regeneron Pharmaceuticals said. Regeneron stock leapt in huge volume.

Amgen's biosimilar drug is close to stealing away sales from AstraZeneca's rare disease drug called Soliris.

Apellis' (APLS) marketed drug, Empaveli, approved for treating paroxysmal nocturnal hemoglobinuria is driving revenues. The drug's label expansion studies also hold promise.

Amylyx Pharmaceuticals Inc. shares were riding high in the first few hours of trading following a key FDA advisory committee's positive vote on its first drug, despite the unusual caveats that accompanied the vote.

Shares of Shuttle Pharmaceuticals Holdings (NASDAQ: SHPH) climbed 160.4% this week, according to data from S&P Global Intelligence. The stock closed at $14.90 last Friday and then opened this Tuesday at $12.16. The stock began trading on Aug. 31 after its initial public offering (IPO).

An emerging crop of drug developers is using artificial intelligence, machine learning, and sometimes supercomputers to design safer and more effective drugs. The latest update from Relay Therapeutics provides early validation for a technology-enabled approach. At the very least, the preliminary data published ahead of an important scientific meeting shows the promise of the company's unique strategy to design more selective drug candidates.

Parkinson's disease (PD) may be an issue that stems from the health and function of your brain, according to the National Institute on Aging. However, a new study recently published by JAMA Network Open also reveals a connection between eating habits and mortality rates for those with PD.In a study titled "Association of Diet and Physical Activity With All-Cause Mortality Among Adults With Parkinson Disease," researchers took a look at 1,251 participants who were previously diagnosed with Parkin

Moderna stock has moved entirely on the perceived fortunes of its Covid-19 vaccine. Now, the company and analysts say, investors should look deeper into the pipeline.

It seems like every major technology company wants to disrupt healthcare. It's easy to see why as the United States spends nearly 18% of its gross domestic product (GDP) on healthcare. "...Because national health expenditures are projected to grow 1.1 percentage points faster than gross domestic product per year on average over 2019-28, the health share of the economy is projected to rise from 17.7% in 2018 to 19.7% in 2028."

AstraZeneca plc (NASDAQ: AZN) and Merck & Co Inc (NYSE: MRK) announced long-term follow-up results from the Phase 3 PAOLA-1 and SOLO-1 trials in first-line advanced ovarian cancer evaluating Lynparza (Olaparib) as a combination and monotherapy. The companies said the data represents the longest-term data for any PARP inhibitor in this setting. The Phase 3 PAOLA-1 trial evaluated Lynparza combined with bevacizumab as first-line maintenance therapy. Final overall survival (OS) in Lynparza plus bev

An Etowah County, Alabama, jail is detaining several pregnant women and new moms for allegedly using drugs while pregnant. None of the women, at least two of whom are Black, have been convicted despite being held in jail for months.

A Pennsylvania woman is claiming that she spent four days in the hospital after biting into a scrap of metal in her chicken fries order from Burger King.

Scott Taylor never got to move on from COVID-19. The analysis was based on data from 20 major U.S. hospital systems, including more than 1.3 million adults with a COVID diagnosis and 19,000 with a long COVID diagnosis between May 2020 and July 2022.

The White House is pushing Americans to get the updated Covid booster ahead of a potential fall surge of the virus. The new shots target the BA.5 omicron subvariant.

Analysts say the drug, from Revance Therapeutics, poses a threat to the market-dominating antiwrinkle treatment because it promises to last longer.

Teva Pharmaceutical Industries Ltd (NYSE: TEVA) announced the results of two studies presented at the Migraine Trust International Symposium (MTIS). The data demonstrate the efficacy of Ajovy (fremanezumab) in migraine patients who also experience depression or anxiety. Ajovy is indicated to prevent migraine in adults with at least four migraine days per month. In both studies, quarterly and monthly dosing of fremanezumab demonstrated efficacy in reducing monthly migraine attacks by more than 50